It is noteworthy that one of the identified compounds, ZINC114898570 (fruquintinib), was a potent and highly selective small molecule inhibitor of VEGFRs, including the VEGFR2 protein, approved in China for use in the treatment of metastatic colorectal cancer (CRC) and currently under Fast Track designation in the FDA for the USA. Here, KDR is linked to colorectal carcinoma.